Skip to Content

MURANO study supports the use of fixed-duration VenR in R/R CLL

Final 7-year follow-up findings from the MURANO study were revealed at this EHA 23’ congress. In this MEDtalk, professor of Translational Hematology Aron Kater presents the results indicating meaningful progression-free survival of patients with relapsed/refractory chronic lymphatic leukemia (R/R CLL) treated with venetolax-rituximab (VenR).

Arnon Kater

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top